glp-1 cancer risk Long-term in users of agonists in Denmark: a nationwide emulated trial Frontiers | Reassessing cancer risk

Description

This article identifies the sources and targets of GLP-1 in the brain and review the mechanisms which mediate its neuroprotective effects, as well as implications for Alzheimers disease (AD) and Parkinsons disease (PD)

Some plan types, such as private fee-for-service plans and PACE, are not eligible unless you also have a standalone PDP

Ultimately, microdosing sounds appealing, but its results arent guaranteed or backed by much evidence

Tirzepatide came off the FDAs official drug shortage list in December 2024, and semaglutide followed in February 2025, eliminating the legal pathway that allowed compounding pharmacies to produce copies of the drugs

Such evidence has been corroborated by trials showing nephroprotective effects of SGLT2i in individuals with CKD of any origin, with or without type 2 diabetes [8, 9]